Pre-made Dalutrafusp benchmark antibody ( Whole mAb, anti-TGFBR2 therapeutic antibody, Anti-AAT3/FAA3/LDS1B/LDS2/LDS2B/MFS2/RIIC/TAAD2/TBR-ii/TBRII/TGFR-2-RII Antibody) for drug discovery and mechanism of action (MOA) research
* GeneMedi provides NON-PROFIT PRICE to support Academic research. Please click inquiry for product quotation. → Inquiry
Product Details
Pre-Made Dalutrafusp biosimilar, Whole mAb, Anti-TGFBR2 Antibody: Anti-AAT3/FAA3/LDS1B/LDS2/LDS2B/MFS2/RIIC/TAAD2/TBR-ii/TBRII/TGFR-2-RII therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
| Products Name (INN Index) | Pre-Made Dalutrafusp biosimilar, Whole mAb, Anti-TGFBR2 Antibody: Anti-AAT3/FAA3/LDS1B/LDS2/LDS2B/MFS2/RIIC/TAAD2/TBR-ii/TBRII/TGFR-2-RII therapeutic antibody |
|---|---|
| INN Name | Dalutrafusp |
| Target | TGFBR2 |
| Format | Whole mAb Fusion |
| Derivation | Humanized |
| Species Reactivity | Human |
| CH1 Isotype | G1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Phase-I |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2021 |
| Year Recommended | NA |
| Companies | Gilead Sciences |
| Conditions Approved | NA |
| Conditions Active | Solid tumours |
| Conditions Discontinued | NA |
| Development Tech | NA |
| Previous Name | NA |
| Gm Offical Target Name | TGFBR2 |
| Package |
